| [1] |
Sorodoc V, Indrei L, Dobroghii C, et al. Amiodarone therapy: Updated practical insights[J]. Journal of Clinical Medicine, 2024, 13(20): 6094.
|
| [2] |
Kowey PR, Marinchak RA, Rials SJ, et al. Intravenous amiodarone[J]. Journal of the American College of Cardiology, 1997, 29(6): 1190-1198.
|
| [3] |
Mujoviĉ N, Dobrev D, Marinkoviĉ M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias[J]. Pharmacological Research, 2020, 151: 104521.
|
| [4] |
Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone[J]. Clinical pharmacokinetics, 1984, 9(2): 136-156.
|
| [5] |
Saigal K, Sussmane S, Tuli S. Corneal Amiodarone Deposition and Its Implications for Autologous Serum Eye Drop Therapy: A Case Report[J]. Cureus, 2025, 17(11): e96670..
|
| [6] |
Martin WJ, Kachel DL, Vilen T, et al. Mechanism of phospholipidosis in amiodarone pulmonary toxicity[J]. The Journal of pharmacology and experimental therapeutics, 1989, 251(1): 272-278.
|
| [7] |
Yoon JJ, Ismail S, Sherwin T. Limbal stem cells: Central concepts of corneal epithelial homeostasis[J]. World journal of stem cells, 2014, 6(4): 391.
|
| [8] |
Dua HS, Watson NJ, Mathur RM, et al. Corneal epithelial cell migration in humans：'hurricane and blizzard keratopathy'[J]. Eye, 1993, 7(1): 53-58.
|
| [9] |
Dua HS, Singh A, Gomes JAP, et al. Vortex or whorl formation of cultured human corneal epithelial cells induced by magnetic fields[J]. Eye, 1996, 10(4): 447-450.
|
| [10] |
Kaplan LJ, Cappaert WE. Amiodarone-induced corneal deposits[J]. Annals of ophthalmology, 1984, 16(8): 762-766.
|
| [11] |
Ikegawa Y, Shiraishi A, Hayashi Y, et al. In Vivo Confocal Microscopic Observations of Vortex Keratopathy in Patients with Amiodarone-Induced Keratopathy and Fabry Disease[J]. Journal of Ophthalmology, 2018: 5315137.
|
| [12] |
D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease[J]. Archives of Ophthalmology, 1981, 99(2): 257-261.
|
| [13] |
Orlando RG, Dangel ME, Schaal SF. Clinical experience and grading of amiodarone keratopathy[J]. Ophthalmology, 1984, 91(10): 1184-1187.
|
| [14] |
Nielsen CE, Andreasen F, Bjerregaard P. Amiodarone induced cornea verticillata[J]. Acta Ophthalmologica, 1983, 61(3): 474-480.
|
| [15] |
Ciancaglini M, Carpineto P, Zuppardi E, et al. In vivo confocal microscopy of patients with amiodarone-induced keratopathy[J]. Cornea, 2001, 20(4): 368-373.
|
| [16] |
Victor G, Alves MR, Nosé W. In vivo confocal microscopy in amiodarone corneal deposits[J]. Arquivos Brasileiros de Oftalmologia, 2007, 70: 45-50.
|
| [17] |
Inoue H, Toriyama K, Joko T, et al. In vivo confocal microscopic images of atypical amiodarone-induced keratopathy in patient with epithelial basement membrane dystrophy[J]. American journal of ophthalmology case reports, 2021, 22: 101105.
|
| [18] |
Uĉakhan ÖÖ，Kanpolat A, Ylmaz N, et al. Amiodarone keratopathy: an in vivo confocal microscopy study[J]. Eye & contact lens, 2005, 31(4): 148-157.
|
| [19] |
Andres J. Ophthalmic Toxicities of Systemic Drug Therapy[J]. US Pharm, 2015, 6: 23.
|
| [20] |
胡茂生，王秀英. 乙胺碘呋酮引起角膜色素沉着(30例临床观察)[J]. 眼科研究，1983，4(2)：116-117.
|
| [21] |
Alshehri M, Joury A. Ocular adverse effects of amiodarone: a systematic review of case reports[J]. Optometry and Vision Science, 2020, 97(7): 536-542.
|
| [22] |
Mehta S, Bunya VY, Orlin SE, et al. A significant drug-drug interaction detected through corneal examination: resolution of cornea verticillata while using amiodarone[J]. Cornea, 2012, 31(1): 81-83.
|
| [23] |
Schiffmann R, Fuller M, Clarke LA, et al. Is it Fabry disease？[J]. Genetics in Medicine, 2016, 18(12): 1181-1185.
|
| [24] |
Schiffmann R. Fabry disease[J]. Pharmacology & therapeutics, 2009, 122(1): 65-77.
|
| [25] |
Zhou X, Li Y, Zhao Y, et al. Corneal neuro-immune crosstalk in Fabry disease: An in vivo confocal microscopic study[J]. Journal of Neuroimmunology, 2025: 578759.
|
| [26] |
Mastropasqua L, Nubile M, Lanzini M, et al. Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study[J]. American journal of ophthalmology, 2006, 141(4): 709-709.
|
| [27] |
Yamagiwa Y, Haranosono Y, Nemoto S, et al. Characteristics of corneal phospholipidosis induced by topical ocular application of chloroquine and amiodarone in rabbits[J]. Journal of Toxicologic Pathology, 2017, 30(2): 135-143.
|
| [28] |
Ma X, He L, He D, et al. Chloroquine keratopathy of rheumatoid arthritis patients detected by in vivo confocal microscopy[J]. Current Eye Research, 2012, 37(4): 293-299.
|
| [29] |
Paulose RM, Chhablani J, Jhingan M. Update on hydroxychloroquine retinopathy[J]. Kerala Journal of Ophthalmology, 2017, 29(1): 9-13.
|
| [30] |
Paladini I, Menchini U, Mencucci R. In vivo confocal microscopy in chloroquine-induced keratopathy[J]. Middle East African Journal of Ophthalmology, 2013, 20(1): 77-79.
|
| [31] |
Ma X, He L, He D, et al. Chloroquine keratopathy of rheumatoid arthritis patients detected by in vivo confocal microscopy[J]. Current Eye Research, 2012, 37(4): 293-299.
|
| [32] |
Sams WM. Chloroquine: mechanism of action[J]. Mayo Clinic Proceedings. Elsevier, 1967, 42(5): 300-309.
|
| [33] |
Tomatsu S, Pitz S, Hampel U. Ophthalmological findings in mucopolysaccharidoses[J]. Journal of clinical medicine, 2019, 8(9): 1467.
|
| [34] |
Williams IM, Pineda R, Neerukonda VK, et al. Mucopolysaccharidosis Type I-Associated Corneal Disease: A Clinicopathologic Study[J]. American Journal of Ophthalmology, 2021, 231: 39-47.
|
| [35] |
Nagueh SF. Anderson-Fabry disease and other lysosomal storage disorders[J]. Circulation, 2014, 130(13): 1081-1090.
|
| [36] |
Matoba A, Oie Y, Tanibuchi H, et al. Anterior segment optical coherence tomography and in vivo confocal microscopy in cases of mucopolysaccharidosis[J]. American Journal of Ophthalmology Case Reports, 2020, 19: 100728.
|
| [37] |
Alroy J, Haskins M, Birk DE. Altered corneal stromal matrix organization is associated with mucopolysaccharidosis I, III and VI[J]. Experimental eye research, 1999, 68(5): 523-530.
|
| [38] |
Del Longo A, Piozzi E, Schweizer F. Ocular features in mucopolysaccharidosis: diagnosis and treatment[J]. Italian journal of pediatrics, 2018, 44(Suppl 2): 125.
|
| [39] |
Maisuria NG, Shah K, Das M, et al. Ocular Toxicity Of Phenothiazine[J]. Haryana Journal Of Ophthalmology, 2022, 14(2): 60-62.
|
| [40] |
Pouget R, Blayac JP, Largey B, et al. Corneal and lens deposits due to treatment by phenothiazine type neuroleptics[J]. Annales Médico-Psychologiques. 1976, 1(3): 403-407.
|
| [41] |
Razeghinejad MR, Nowroozzadeh MH, Zamani M, et al. In vivo observations of chlorpromazine ocular deposits in a patient on long-term chlorpromazine therapy[J]. Clinical & Experimental Ophthalmology, 2008, 36(6): 560-563.
|
| [42] |
Raizman MB, Hamrah P, Holland EJ, et al. Drug-induced corneal epithelial changes[J]. Survey of ophthalmology, 2017, 62(3): 286-301.
|
| [43] |
Kaštelan S, Gabriĉ K, Mikuliĉiĉ M, et al. The influence of tear film quality on visual function[J]. Vision, 2024, 8(1): 8.
|
| [44] |
Wu H, Lin Z, Yang F, et al. Meibomian gland dysfunction correlates to the tear film instability and ocular discomfort in patients with pterygium[J]. Scientific reports, 2017, 7(1): 45115.
|
| [45] |
Wei Z, Su Y, Su G, et al. Effect of artificial tears on dynamic optical quality in patients with dry eye disease[J]. BMC ophthalmology, 2022, 22(1): 64.
|